A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease

Trial Profile

A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Psychotic disorders
  • Focus Therapeutic Use
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 03 Nov 2017 Data presented in an ACADIA Pharmaceuticals Media Release.
    • 03 Nov 2017 According to an ACADIA Pharmaceuticals media release, data were presented at the 10th Clinical Trials on Alzheimers Disease (CTAD) meeting.
    • 04 Oct 2017 According to an Acadia Pharmaceuticals media release, results from this trial will be presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD) Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top